Moderna lowers forecast for 2021 COVID-19 vaccine deliveries
ABC News
Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year
Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year and the revenue it will record from them.
Longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may shift some deliveries to early 2022, the drugmaker said Thursday. The company now expects full-year, 2021 product sales of between $15 billion and $18 billion.
That’s down from a prediction for $20 billion in sales that it made in August.
Moderna’s COVID-19 vaccine is the only product the drugmaker has on the market. It brought in $4.81 billion in sales during the third quarter, up from $4.2 billion the previous quarter.